Managing depressive and anxiety disorders with escitalopram

Bibliography

• MURRAY CJL, LOPEZ AD: Evidence-based health policy – lessons from the Global Burden of Disease Study. Science (1996) 274(5288):740-741.
   PubMed Web of Science ®Google Scholar
• EDWARDS JG, ANDERSON I: Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs (1999) 57:507-533.
   PubMed Web of Science ®Google Scholar
• THASE ME, KUPFER DJ: Recent developments in the pharmacotherapy of mood disorders. J. Consult. Clin. Psychol. (1996) 64:646-659.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY SA, HENRY J, MCDONALD G et al.: Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int. Clin. Psychopharmacol. (1994) 9:47-53.
   PubMed Web of Science ®Google Scholar
• BUCKLEY NA, MCMANUS PR: Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. Br. Med J. (2002) 325(7376):1332-1333.
   PubMed Web of Science ®Google Scholar
• DEMYTTENAERE K, MESTERS P, BOULANGER B et al.: Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine. J. Affect. Disord. (2001) 65:243-252.
   PubMedGoogle Scholar
• ANDERSON IM, TOMENSON BM: The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J. Psychopharmacol. (1994) 8:238-249.
   PubMed Web of Science ®Google Scholar
• ANDERSON IM: Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord. (2000) 58:19-36.
   PubMed Web of Science ®Google Scholar
• FREEMANTLE N, ANDERSON IM, YOUNG P: Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Br. J. Psychiatry. (2000) 177:292-302.
   PubMed Web of Science ®Google Scholar
• ANDERSON IM: SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress. Anxiety (1998) 7(Suppl. 1):11-17.
   PubMedGoogle Scholar
• NELSON JC: Augmentation strategies with serotonergic-noradrenergic combinations. J. Clin. Psychiatry (1998) 59(Suppl. 5):65-68.
   PubMedGoogle Scholar
• THASE ME, ENTSUAH AR, RUDOLPH RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry (2001) 178:234-241.
   PubMed Web of Science ®Google Scholar
• SMITH D, DEMPSTER C, GLANVILLE J, FREEMANTLE N, ANDERSON I: Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br. J. Psychiatry (2002) 180:396-404.
   PubMed Web of Science ®Google Scholar
• KENNEDY SH, EMSLEY R: Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol. (2005) [Epub ahead of print].
   Google Scholar
• OWENS MJ, KNIGHT DL, NEMEROFF CB: Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry (2001) 50:345-350.
   PubMed Web of Science ®Google Scholar
• NIKISCH G, MATHE AA, CZERNIK A et al.: Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. J. Clin. Psychopharmacol. (2004) 24:283-290.
   PubMed Web of Science ®Google Scholar
• NIKISCH G, MATHE AA, CZERNIK A et al.: Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology (2005) 181:751-760.
   PubMedGoogle Scholar
• CHEN F, LARSEN MB, SANCHEZ C, WIBORG O: The S-enantiomer of R, S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur. Neuropsychopharmacol. (2005) 15:193-198.
   PubMed Web of Science ®Google Scholar
• SANCHEZ C, BOGESO KP, EBERT B, REINES EH, BRAESTRUP C: Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacol. (2004) 174:163-176.
   PubMed Web of Science ®Google Scholar
• STORUSTOVU S, SANCHEZ C, PORZGEN P et al.: R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br. J. Pharmacol. (2004) 142:172-180.
   PubMed Web of Science ®Google Scholar
• EL MANSARI M, SANCHEZ C, CHOUVET G, RENAUD B, HADDJERI N: Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacol. (2005) 30:1269-1277.
   PubMed Web of Science ®Google Scholar
• SANCHEZ C, KREILGAARD M: R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol. Biochem. Behav. (2004) 77:391-398.
   PubMed Web of Science ®Google Scholar
• SANCHEZ C, GRUCA P, PAPP M: R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav. Pharmacol. (2003) 14:465-470.
   PubMed Web of Science ®Google Scholar
• MEYER JH, WILSON AA, SAGRATI S et al.: Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am. J. Psychiatry (2004) 161:826-835.
   PubMed Web of Science ®Google Scholar
• DEVANE CL, BOULTON DW: Great expectations in stereochemistry: focus on antidepressants. CNS Spectr. (2002) 7(Suppl. 1):28-33.
   PubMedGoogle Scholar
• SOGAARD B, MENGEL H, RAO N, LARSEN F: The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J. Clin. Pharmacol. (2005) 45:1400-1406.
   PubMed Web of Science ®Google Scholar
• VON MOLTKE LL, GREENBLATT DJ, GIANCARLO GM, GRANDA BW, HARMATZ JS, SHADER RI: Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab. Dispos. (2001) 29:1102-1109.
   PubMed Web of Science ®Google Scholar
• MURDOCH D, KEAM SJ: Escitalopram: a review of its use in the management of major depressive disorder. Drugs (2005) 65:2379-2404.
   PubMed Web of Science ®Google Scholar
• BALDWIN DS, NAIR RV: Escitalopram in the treatment of generalized anxiety disorder. Expert Rev. Neurother. (2005) 5:443-449.
   PubMedGoogle Scholar
• BALDWIN DS, POLKINGHORN C: Evidence-based pharmacotherapy of generalized anxiety disorder. Int. J. Neuropsychopharmacol. (2005) 8:293-302.
   PubMed Web of Science ®Google Scholar
• BURKE WJ, GERGEL I, BOSE A: Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J. Clin. Psychiatry (2002) 63:331-336.
   PubMed Web of Science ®Google Scholar
• NINAN PT, VENTURA D, WANG J: Escitalopram is effective and well tolerated in the treatment of severe depression. Presented at the 156th Annual Meeting of the American Psychiatric Association. San Francisco, USA (2003).
   Google Scholar
• FOREST LABORATORIES I: Flexible dose comparison of the safety and efficacy of escitalopram, citalopram and placebo in the treatment of major depressive disorder. Forest Laboratories, Inc., New York, NY, USA (2003) (Unpublished data).
   Google Scholar
• WADE A, LEMMING M, HEDEGAARD B: Escitalopram 10mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol. (2002) 17:95-102.
   PubMed Web of Science ®Google Scholar
• LEPOLA UM, LOFT H, REINES EH: Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol. (2003) 18:211-217.
   PubMed Web of Science ®Google Scholar
• KASPER S, DE SWART H, FRIIS ANDERSEN H: Escitalopram in the treatment of depressed elderly patients. Am. J. Geriatr. Psychiatry (2005) 13:884-891.
   PubMed Web of Science ®Google Scholar
• BECH P, TANGHOJ P, CIALDELLA P, ANDERSEN HF, PEDERSEN AG: Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int. J. Neuropsychopharmacol. (2004) 7:283-290.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY SA, ÅSBERG M: A new depression scale designed to be sensitive to change. Br. J. Psychiatry (1979) 134:382-389.
   PubMed Web of Science ®Google Scholar
• COLONNA L, ANDERSEN HF, REINES EH: A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr. Med. Res. Opin. (2005) 21:1659-1668.
   PubMed Web of Science ®Google Scholar
• MOORE N, VERDOUX H, FANTINO B: Prospective, multicenter, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int. Clin. Psychopharmacol. (2005) 20:131-137.
   PubMed Web of Science ®Google Scholar
• THASE ME: Comparing the methods used to compare antidepressants. Psychopharmacol. Bull. (2002) 36(Suppl. 1):1-17.
   Google Scholar
• KHAN A, WARNER HA, BROWN WA: Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch. Gen. Psychiatry (2000) 57:311-317.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN JA, GREENHOUSE J, HAMER RM et al.: Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology (2005) 30:445-460.
   PubMed Web of Science ®Google Scholar
• GORMAN JM, KOROTZER A, SU G: Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrums (2002) 7(Suppl. 1):40-44.
   PubMed Web of Science ®Google Scholar
• AUQUIER P, ROBITAIL S, LLORCA PM, RIVE B: Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int. J. Psychiatry Clin. Prac. (2003) 7:259-268.
   PubMed Web of Science ®Google Scholar
• LEPOLA U, WADE, ANDERSON HF: Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int. Clin. Psychopharmacol. (2004) 19:149-155.
   PubMed Web of Science ®Google Scholar
• LORCA P-M, AZORIN J-M, DESPIEGEL N, VERPILLA P: Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int. J. Clin. Pract. (2005) 59:268-275.
   PubMedGoogle Scholar
• MONTGOMERY SA, HUUSOM AK, BOTHMER J: A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobioliogy (2004) 50:57-64.
   PubMed Web of Science ®Google Scholar
• BIELSKI RJ, VENTURA D, CHANG C-C: A double-blind comparison of escitalopram with venlafaxine XR in the treatment of major depressive disorder. J. Clin. Psychiatry (2004) 65:1190-1196.
   PubMed Web of Science ®Google Scholar
• RAPAPORT NH, BOSE A, ZHENG H: Escitalopram continuation treatment prevents relapse in depressive episodes. J. Clin. Psychiatry (2004) 65:44-49.
   PubMed Web of Science ®Google Scholar
• STAHL S, GERGEL I, LI D: Escitalopram in the treatment of panic disorder: a randomised, double-blind, placebo-controlled trial. J. Clin. Psychiatry (2003) 64:1322-1327.
   PubMed Web of Science ®Google Scholar
• SHEEHAN DV, BURNHAM DB, IYENGAR MK, PERERA P: Paxil CR Panic Disorder Study Group. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J. Clin. Psychiatry (2005): 66:34-40.
   PubMed Web of Science ®Google Scholar
• HAMILTON M: Diagnosis and rating of anxiety. Br. J. Psychiatry (1969) 3:76-79.
   Google Scholar
• DAVIDSON JR, BOSE A, KOROTZER A, ZHENG H: Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress. Anxiety (2004) 19:234-240.
   PubMed Web of Science ®Google Scholar
• GOODMAN WK, BOSE A, WANG Q: Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J. Affect. Disord. (2005) 87:161-167.
   PubMed Web of Science ®Google Scholar
• DAVIDSON JRT, CONNER KM, BOSE A, WANG Q: Escitalopram in the long-term treatment of generalized anxiety disorder. Poster presented at the 24th annual conference of the Anxiety Disorders Association of America. Miami, Florida, USA (2004).
   Google Scholar
• ALLGULANDER C, FLOREA I, HUUSOM AK: Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int. J. Neuropsychopharmacol. (2005) 6:1-11.
   Google Scholar
• BALDWIN DS, HUUSOM AKT, MAEHLUM E: Escitalopram and paroxetine compared to placebo in generalized anxiety disorder. Eur. Neuropsychopharmacol. (2004) 19(Suppl. 1):S224.
   Google Scholar
• BIELSKI RJ, BOSE A, CHANG CC: A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann. Clin. Psychiatry (2005) 17:65-69.
   PubMedGoogle Scholar
• LADER M, STENDER K, BÜRGER V, NIL R: The efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress. Anxiety (2004) 19:241-248.
   PubMed Web of Science ®Google Scholar
• KASPER S, STEIN DJ, LOFT H, NIL R: Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br. J. Psychiatry (2005) 186:222-226.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY SA, NIL R, DURR-PAL N, LOFT H, BOULENGER JP: A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J. Clin. Psychiatry (2005) 66:1270-1278.
   PubMed Web of Science ®Google Scholar
• FRESCO DM, COLES ME, HEIMBERG RG et al.: The Liebowitz Social Anxiety Scale: a comparison of the psychometric properties of self-report and clinician-administered formats. Psychol. Med. (2001) 31:1025-1035.
   PubMed Web of Science ®Google Scholar
• STEIN DJ, ANDERSON EW, LADER M: Escialopram versus paroxetine for social anxiety disorder: An analysis of efficacy for fidderent symptom dimensions. Eur. Neuropsychopharmacol. (2006) 16(1):33-38.
   PubMedGoogle Scholar
• WAGNER KD: Pharmacotherapy for major depression in children and adolescents. Prog. Neuropsychopharmacol. Biol. Psychiatry. (2005) 29:819-826.
   PubMedGoogle Scholar
• VALUCK RJ, LIBBY AM, SILLS MR, GIESE AA, ALLEN RR: Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs (2004) 18:1119-1132.
   PubMed Web of Science ®Google Scholar
• WONG IC, BESAG FM, SANTOSH PJ, MURRAY ML: Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Saf. (2004) 27:991-1000.
   PubMed Web of Science ®Google Scholar
• WHITTINGTON CJ, KENDALL T, FONAGY P, COTTRELL D, COTGROVE A, BODDINGTON E: Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet (2004) 363(9418):1341-1345.
   PubMed Web of Science ®Google Scholar
• WAGNER KD, ROBB AS, FINDLING RL, JIN J, GUTIERREZ MM, HEYDORN WE: A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am. J. Psychiatry. (2004) 161:1079-1083.
   PubMed Web of Science ®Google Scholar
• PEDERSEN AG: Escitalopram and suicidality in adult depression and anxiety. Int. Clin. Psychopharmacol. (2005) 20:139-143.
   PubMed Web of Science ®Google Scholar
• BALON R: The effects of antidepressants on human sexuality: diagnosis and management. Primary Psychiatry (1995) 2:46-51.
   Google Scholar
• ASHTON AK, MAHMOOD A, IQBAL F: Improvements in SSRI/SNRI-induced sexual dysfunction by switching to escitalopram. J. Sex & Marital Therapy (2005) 31:257-262.
   PubMed Web of Science ®Google Scholar
• SVENSSON S, MANSFIELD PR: Escitalopram: superior to citalopram or a chiral chimera? Psychother. Psychosom. (2004) 73:10-16.
   PubMed Web of Science ®Google Scholar
• WADE AG, TOUMI I, HEMELS ME: A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin. Ther. (2005) 27:486-496.
   PubMed Web of Science ®Google Scholar
• HEMELS ME, KASPER S, WALTER E, EINARSON TR: Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann. Pharmacother. (2004) 38:954-960.
   PubMed Web of Science ®Google Scholar
• WADE AG, TOUMI I, HEMELS ME: A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr. Med. Res. Opin. (2005) 21:631-642.
   PubMed Web of Science ®Google Scholar
• DEMYTTENAERE K, HEMELS ME, HUDRY J, ANNEMANS L: A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin. Ther. (2005) 27:111-124.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ JL, MONTGOMERY S, FRANCOIS C: Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics (2005) 23:155-167.
   PubMed Web of Science ®Google Scholar